An act to direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency
PL 115-411 (H.R.1660), enacted 01/03/2019

132 STAT. 5424 
PUBLIC LAW 115–411—JAN. 3, 2019 
Public Law 115–411 
115th Congress 
An Act 
To direct the Administrator of the United States Agency for International Develop-
ment to submit to Congress a report on the development and use of global 
health innovations in the programs, projects, and activities of the Agency. 
Be it enacted by the Senate and House of Representatives of 
the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Global Health Innovation Act 
of 2017’’. 
SEC. 2. ANNUAL REPORT. 
(a) IN GENERAL.—Not later than 180 days after the date of 
the enactment of this Act, and annually thereafter for a period 
of 4 years, the Administrator of the United States Agency for 
International Development shall submit to Congress a report on 
the development and use of global health innovations in the pro-
grams, projects, and activities of the Agency. 
(b) MATTERS TO BE INCLUDED.—The report required by sub-
section (a) shall include the following: 
(1) A description of— 
(A) the extent to which global health innovations 
described in subsection (a) include drugs, diagnostics, 
devices, vaccines, electronic and mobile health technologies, 
and related behavior change and service delivery innova-
tions; 
(B) how innovation has advanced the Agency’s commit-
ments to achieving an HIV/AIDS-free generation, ending 
preventable child and maternal deaths, and protecting 
communities from infectious diseases, as well as furthered 
by the Global Health Strategic Framework; 
(C) how goals are set for health product development 
in relation to the Agency’s health-related goals and how 
progress and impact are measured towards those goals; 
(D) how the Agency’s investments in innovation relate 
to its stated goals; and 
(E) progress made towards health product development 
goals. 
(2) How the Agency, both independently and with partners, 
donors, and public-private partnerships, is— 
(A) leveraging United States investments to achieve 
greater impact in health innovation; 
(B) engaging in activities to develop, advance, and 
introduce affordable, available, and appropriate global 
health products; and 
Time period. 
Global Health 
Innovation Act 
of 2017. 
Jan. 3, 2019 
[H.R. 1660] 
VerDate Sep 11 2014 
14:16 Jan 18, 2024
Jkt 079194
PO 00000
Frm 00996
Fmt 6580
Sfmt 6581
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 4\79194PT4.001
79194PT4
whamilton on LAP1Z6H6L3PROD with STATUTES
132 STAT. 5425 
PUBLIC LAW 115–411—JAN. 3, 2019 
LEGISLATIVE HISTORY—H.R. 1660: 
CONGRESSIONAL RECORD, Vol. 164 (2018): 
Jan. 17, 18, considered and passed House. 
Dec. 20, considered and passed Senate. 
(C) scaling up appropriate health innovations in the 
development pipeline. 
(3) A description of collaboration and coordination with 
other Federal departments and agencies, including the Centers 
for Disease Control and Prevention, in support of global health 
product development, including a description of how the Agency 
is working to ensure critical gaps in product development for 
global health are being filled. 
(4) A description of how the Agency is coordinating and 
aligning global health innovation activities between the Global 
Development Lab, the Center for Accelerating Innovation and 
Impact, and the Bureau for Global Health. 
Approved January 3, 2019. 
VerDate Sep 11 2014 
14:16 Jan 18, 2024
Jkt 079194
PO 00000
Frm 00997
Fmt 6580
Sfmt 6580
G:\STATUTES\2018\GOVINFO FILES FOR ERIC\PART 4\79194PT4.001
79194PT4
whamilton on LAP1Z6H6L3PROD with STATUTES